Ospedale San Bortolo

Real‐world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

Summary Venetoclax (VEN) plus hypomethylating agents (HMAs) represents the standard of care for newly diagnosed acute myeloid leukaemia (AML) patients unfit for intensive chemotherapy, but prospective real‐world observational data outside randomized clinical trials remain limited...

Prognostic significance of ACADL and MCM2 in meningiomas: Current evidence and clinical implications.

-wildtype, hypermetabolic, and proliferative. The latter two groups have the worst clinical outcomes and are enriched in ACADL and MCM2 expression, suggesting their potential as immunohistochemical surrogates. The revision of the current literature on the expression of these mark...